Oxford Signs Potential $1B ADC Alliance with Menarini
By Nuala Moran
Tuesday, October 30, 2012
LONDON Oxford BioTherapeutics Ltd. (OBT) has landed a "transformational" deal with Menarini, in which the Italian pharma company is to invest €800 million (US$1 billion) in a portfolio of five antibody and antibody-conjugate drugs discovered by OBT.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.